Definium Therapeutics's banner

Definium Therapeutics

@definiumtx • 23,872 subscribers

Definium Therapeutics (formerly MindMed) is a biotech company forging a new era of psychiatry by applying precision to psychedelic medicine.

Shorts

The data is in. Today, we announced positive topline results from Voyage, our first Phase 3 clinical trial of DT120 ODT in generalized anxiety disorder (GAD). Marking our second positive pivotal study readout, these findings underscore our belief in the potential to redefine mental health care. Thank you to the participants, clinical sites, and research partners who helped us achieve this incredible milestone. Learn more here: #MentalHealth #DefiniumTherapeutics #Psychedelics #HealthcareInnovation #GAD

The data is in. Today, we announced positive topline results from Voyage, our first Phase 3 clinical trial of DT120 ODT in generalized anxiety disorder (GAD). Marking our second positive pivotal study readout, these findings underscore our belief in the potential to redefine mental health care. Thank you to the participants, clinical sites, and research partners who helped us achieve this incredible milestone. Learn more here: #MentalHealth #DefiniumTherapeutics #Psychedelics #HealthcareInnovation #GAD

14,481 views

Milestone unlocked 🔓🔑. Today, we announced positive topline results from Emerge, the first Phase 3 study of our pharmaceutical LSD for major depressive disorder (MDD). These results mark a significant step forward in our mission to forge a new era of psychiatry, one with novel treatments that target underlying cause of disease, not just symptoms. For patients who may have run out of options, these results matter. We’re energized by the momentum ahead as we continue pursuing potential new treatment options for the millions of people living with a mental health disorder. Learn more about this significant step:

Milestone unlocked 🔓🔑. Today, we announced positive topline results from Emerge, the first Phase 3 study of our pharmaceutical LSD for major depressive disorder (MDD). These results mark a significant step forward in our mission to forge a new era of psychiatry, one with novel treatments that target underlying cause of disease, not just symptoms. For patients who may have run out of options, these results matter. We’re energized by the momentum ahead as we continue pursuing potential new treatment options for the millions of people living with a mental health disorder. Learn more about this significant step:

19,489 views

Videos

Anya Rossi

sweetdream.ai

SweetDream.ai•Sponsored•Livecam

Watch Anya Live

Anya is streaming live right now! Join her private show and enjoy exclusive content.

Exclusive private shows

1.2k viewers online

Private Show

Join now for exclusive access

Free preview available • Premium content

This just in: exciting news as we continue to #RaiseTheBar for patients facing unmet needs in mental health. The U.S. Food and Drug Administration (U.S. FDA) has granted Breakthrough Therapy designation to DT120 ODT for the treatment of major depressive disorder (MDD), building on our initial designation in generalized anxiety disorder (GAD). Receiving a second Breakthrough Therapy designation marks a huge leap forward and fuels our momentum toward a potential new generation of therapeutics for patients living with mental health disorders. Read the full announcement here: #MentalHealth #DefiniumTherapeutics #Psychedelics #MDD #Depression #BeyondBetter #HealthcareInnovation

This just in: exciting news as we continue to #RaiseTheBar for patients facing unmet needs in mental health. The U.S. Food and Drug Administration (U.S. FDA) has granted Breakthrough Therapy designation to DT120 ODT for the treatment of major depressive disorder (MDD), building on our initial designation in generalized anxiety disorder (GAD). Receiving a second Breakthrough Therapy designation marks a huge leap forward and fuels our momentum toward a potential new generation of therapeutics for patients living with mental health disorders. Read the full announcement here: #MentalHealth #DefiniumTherapeutics #Psychedelics #MDD #Depression #BeyondBetter #HealthcareInnovation

Definium Therapeutics

13,673 views • 11 days ago

No more content to load